306 related articles for article (PubMed ID: 33327833)
1. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax.
Marques-Piubelli ML; Schlette EJ; Khoury JD; Furqan F; Vega F; Soto LMS; Wistuba II; Wierda WG; Konopleva M; Ferrajoli A; Strati P
Leuk Lymphoma; 2021 May; 62(5):1129-1135. PubMed ID: 33327833
[TBL] [Abstract][Full Text] [Related]
2. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
3. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
[TBL] [Abstract][Full Text] [Related]
4. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
Blombery P; Anderson MA; Gong JN; Thijssen R; Birkinshaw RW; Thompson ER; Teh CE; Nguyen T; Xu Z; Flensburg C; Lew TE; Majewski IJ; Gray DHD; Westerman DA; Tam CS; Seymour JF; Czabotar PE; Huang DCS; Roberts AW
Cancer Discov; 2019 Mar; 9(3):342-353. PubMed ID: 30514704
[TBL] [Abstract][Full Text] [Related]
5. Pathways and mechanisms of venetoclax resistance.
Bose P; Gandhi V; Konopleva M
Leuk Lymphoma; 2017 Sep; 58(9):1-17. PubMed ID: 28140720
[TBL] [Abstract][Full Text] [Related]
6. Landscape of
Kotmayer L; László T; Mikala G; Kiss R; Lévay L; Hegyi LL; Gróf S; Nagy T; Barna G; Farkas P; Weisinger J; Nagy Z; Balogh A; Masszi T; Demeter J; Sulák A; Kohl Z; Alizadeh H; Egyed M; Pettendi P; Gergely L; Plander M; Pauker Z; Masszi A; Matolcsy A; Szász R; Bödör C; Alpár D
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982875
[TBL] [Abstract][Full Text] [Related]
7. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
[TBL] [Abstract][Full Text] [Related]
8. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
9. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
Haselager MV; Kielbassa K; Ter Burg J; Bax DJC; Fernandes SM; Borst J; Tam C; Forconi F; Chiodin G; Brown JR; Dubois J; Kater AP; Eldering E
Blood; 2020 Dec; 136(25):2918-2926. PubMed ID: 32603412
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax.
Avsec D; Škrlj Miklavčič M; Burnik T; Kandušer M; Bizjak M; Podgornik H; Mlinarič-Raščan I
Cell Death Dis; 2022 Oct; 13(10):860. PubMed ID: 36209148
[TBL] [Abstract][Full Text] [Related]
11. SOHO State of the Art Updates and Next Questions | Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions.
Bennett R; Thompson E; Tam C
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):795-804. PubMed ID: 35970756
[TBL] [Abstract][Full Text] [Related]
12. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.
Ten Hacken E; Valentin R; Regis FFD; Sun J; Yin S; Werner L; Deng J; Gruber M; Wong J; Zheng M; Gill AL; Seiler M; Smith P; Thomas M; Buonamici S; Ghia EM; Kim E; Rassenti LZ; Burger JA; Kipps TJ; Meyerson ML; Bachireddy P; Wang L; Reed R; Neuberg D; Carrasco RD; Brooks AN; Letai A; Davids MS; Wu CJ
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282833
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
[TBL] [Abstract][Full Text] [Related]
14. Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies.
Chong SJF; Zhu F; Dashevsky O; Mizuno R; Lai JX; Hackett L; Ryan CE; Collins MC; Iorgulescu JB; Guièze R; Penailillo J; Carrasco R; Hwang YC; Muñoz DP; Bouhaddou M; Lim YC; Wu CJ; Allan JN; Furman RR; Goh BC; Pervaiz S; Coppé JP; Mitsiades CS; Davids MS
J Clin Invest; 2023 Nov; 133(22):. PubMed ID: 37751299
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax resistance and acquired
Tausch E; Close W; Dolnik A; Bloehdorn J; Chyla B; Bullinger L; Döhner H; Mertens D; Stilgenbauer S
Haematologica; 2019 Sep; 104(9):e434-e437. PubMed ID: 31004028
[No Abstract] [Full Text] [Related]
16. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax for the treatment of patients with chronic lymphocytic leukemia.
Crombie J; Davids MS
Future Oncol; 2017 Jun; 13(14):1223-1232. PubMed ID: 28492339
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.
Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS
Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax for the Treatment of Chronic Lymphocytic Leukemia.
Eradat H
Curr Hematol Malig Rep; 2019 Oct; 14(5):469-476. PubMed ID: 31512151
[TBL] [Abstract][Full Text] [Related]
20. Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
Lucas F; Larkin K; Gregory CT; Orwick S; Doong TJ; Lozanski A; Lozanski G; Misra S; Ngankeu A; Ozer HG; Sampath D; Thangavadivel S; Yilmaz SA; Rogers KA; Byrd JC; Woyach JA; Blachly JS
Blood; 2020 Jun; 135(24):2192-2195. PubMed ID: 32232486
[No Abstract] [Full Text] [Related]
[Next] [New Search]
